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Abstract
Growing research indicates oxytocin may be involved in relieving anxiety and attenuating the rewarding
effects of psychostimulants. The present study investigated the effects of subchronic oxytocin
treatments on mesolimbic dopamine transmission in areas associated with anxiety (amygdala) and
addiction (nucleus accumbens, NAc). Using in vivo fixed potential amperometry, stimulation-evoked
dopamine release was recorded either in the amygdala or NAc in oxytocin pretreated mice. During
dopamine recordings, mice received a drug challenge of either oxytocin, the dopamine reuptake blocker
nomifensine (psychostimulant), or saline. In the amygdala, dopamine release was decreased following
the oxytocin challenge but only in oxytocin pretreated mice. In the NAc, baseline dopamine release was
decreased and the dopaminergic response to nomifensine was decreased but only in oxytocin
pretreated mice. Together these results provide neurochemical support for previous behavioral studies
suggesting oxytocin may be useful at treating aspects of anxiety and drug abuse.
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Oxytocin is a neuropeptide synthesized in the supraoptic and paraventricular nuclei of the
hypothalamus. Oxytocin is released into the bloodstream by the pituitary gland thus functioning
as a hormone, but this neuropeptide is also released into the central nervous system thus
additionally functioning as a neuromodulator. Oxytocin has been classically credited with
initiating contractions and assisting in lactation, and has been used for these purposes clinically
for decades (Magon & Kalra, 2011). However, recent studies have shown that oxytocin plays a
variety of roles in physiological and psychological behaviors. For example, oxytocin also has
been shown to influence behaviors related to maternal bonding, stress, memory and learning, and
social bonding (Magon, & Kalra, 2011). Therefore, it is not surprising that oxytocin is being
increasingly applied in clinical settings. Clinically, oxytocin is usually delivered intranasally
(Veening & Oliver, 2013), and as of September 2018, a search for “intranasal oxytocin” on
ClinicalTrials.gov returned 198 ongoing, planned, or completed studies, of which 26 are related
to treating autism, 19 to anxiety or posttraumatic stress disorder, 25 to drug abuse, and 24 to
schizophrenia. Interestingly, most of the therapeutic applications of oxytocin are aimed at
disorders associated with dopamine transmission (Baskerville & Douglas, 2010); however, the
effect of oxytocin administration on dopamine transmission is not yet understood. Both oxytocin
and dopamine receptors and fibers have been shown to exist in corresponding brain regions,
often close in proximity to each other (Ross et al., 2009; Smeltzer, Curtis, Aragona, & Wang,
2006; Love, 2014). Many animal studies have shown that oxytocin and dopamine interact to
affect aspects of social behaviors, stress, and attention (for review see Baskerville & Douglas,
2010; Love, 2014). Furthermore, stimulations of oxytocin and dopamine pathways are known to
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have comparable results on social behaviors such as sexual behaviors and pair bonding
(Baskerville & Douglas, 2010).
Neuronal dopamine cell bodies predominately originate in the ventral tegmental area
(VTA) and the substantia nigra pars compacta (SNc), and have 3 main projection pathways. The
nigrostriatal dopamine pathway has projections from the SNc to the dorsal striatum within the
basal ganglia and is important for healthy motor functioning (Lester, Rogers, & Blaha, 2010).
The mesocortical dopamine pathway projects from the VTA to the prefrontal cortex and is
associated with emotional behavior and cognition (Goldin, McRae, Ramel, & Gross, 2008;
Bechara, Damasio, Damasio, & Lee, 1999). The mesolimbic dopamine pathway consists of
projections from the VTA to areas within the limbic system, specifically the nucleus accumbens
(NAc) and amygdala. Dopamine transmission in the NAc is associated with attention and
reward-motivated behaviors (O’brien & Gardner, 2005; Salgado & Kaplitt, 2015; Volkow et al.,
2006), while the amygdala is involved in regulation of fear, anxiety, and emotional intelligence
(Anderson & Phelps, 2000; LeDoux, 2007; LaBar, Gatenby, Gore, LeDoux, & Phelps, 1998).
Abnormalities of dopamine systems are considered to be contributors to Parkinson’s disease,
schizophrenia, major depressive disorders, attention-deficit hyperactivity disorder, anxiety,
addiction, binge eating, and compulsive disorders (Baskerville & Douglas, 2010).

Anxiety
Anxiety is a behavioral state with physiological and psychological changes due to
environmental threats, either perceived or real. The threat causes involuntary responses that
include an increased state of arousal and reflexive responses from the autonomic nervous system
and the endocrine system. The autonomic nervous system is constantly at work maintaining a
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balance of internal functions; however, when one encounters or perceives a danger, this system
reacts. The initial response prepares our bodies for action, generally by increasing heart rate,
blood pressure, and muscle tension while slowing immune responses and digestion (Steimer,
2002). When danger is evaded, or deemed unrealistic, homeostasis resumes, and the body
relaxes. Anxiety is a necessary, normal reaction to the environment and assists in survival.
Anxiety-related behaviors become maladaptive, however, when they are displayed at an
excessive degree relative to the threat level or in response to uncertain and unlikely threat
(Brosschot, Verkuil, & Thayer, 2016; Grupe & Nitschke, 2013). Unfortunately, the occurrence
of faulty perceptions regarding threat assessment and consequently increased unwarranted
anxiety are commonplace in our species.
Imaging studies have repeatedly shown structural damage and/or functional alterations in
the amygdala of patients with chronic anxiety disorder, post-traumatic stress disorder, social
anxiety, and depressive disorders (Holzel et al., 2009; Pine, 2007). The neural connections of the
amygdala highlight its role in regulating emotional behaviors. The amygdala receives sensory
input from thalamic and cortical regions, which is then integrated and potentially sent as a
distress signal to the hypothalamus. This begins the activation of the autonomic nervous system
via excitation of the hypothalamus-pituitary-adrenal (HPA) axis, resulting in release of cortisol
throughout the body (McEwen, 2007). The amygdala also projects to the prefrontal cortex,
hippocampus, and striatum to allow an evaluation of the situation, planning motor responses, and
an opportunity to code information into memory (Pine, 2007). This reciprocal connection
between the prefrontal cortex and the amygdala ultimately keeps amygdala activity in check.
The prefrontal cortex has inhibitory projections that can reduce amygdala activation when the
environmental situation does not require a fear/anxiety response (Ochsner et al., 2004; Urry et
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al., 2006; Ohira et al., 2006). Thus, the balance between excitatory and inhibitory activity in the
amygdala influences the anxiety state of animal.
Dopamine plays a role in regulating activity levels of the amygdala and has been
associated with anxiety (Zarrindast & Khakpai, 2015). Under stress, dopamine neurons are
activated in the VTA leading to increased release of dopamine in the amygdala and increased
occurrence of anxiety-related behaviors (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989;
Borowski & Kokkindis, 1998; Forster, Novick, Scholl, & Watt, 2012; de la Mora, Gallegos-Cari,
Arizmendi-Garcia, Marcellino, & Fuxe, 2010). Dopamine release in the amygdala is thought to
potentiate anxiety by dampening the inhibition of amygdala activity maintained by the prefrontal
cortex (Diaz, Chappell, Christian, Anderson, & McCool, 2011). Lesions of the VTA were
shown to attenuate conditioned fear behavior and responses (de la Mora et al, 2010), and
research suggests that the administration of some anxiolytic drugs reduces amygdalar dopamine
release evoked by exposure to aversive stimuli (Coco, Kuhn, Ely, & Kilts, 1992). The general
mechanism of most anxiolytic medications includes reducing activity of the amygdala.
The most commonly used anxiolytics, a class of drugs called benzodiazepines (such as
Valium and Xanax), reduce neurotransmission in the amygdala by agonizing the inhibitory
neurotransmitter GABA (Davis, Rainnie, & Cassell, 1994; Sanders & Shekhar, 1995).
Unfortunately, patients using these as chronic treatments are at risk for developing
benzodiazepine dependence (Farach et al., 2012). In 2016, over 10,000 adults died from
overdose involving a benzodiazepine; this accounts for nearly 15% of all overdose-related deaths
[National Institute on Drug Abuse (NIDA), 2018]. Such problems caution the use of
benzodiazepines for treating chronic anxiety and have physicians seeking alternate
pharmaceuticals. Some patients are prescribed antidepressants for chronic treatment of anxiety;
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however, these medications have substantial non-response rates (e.g. 44%) and can lead to
increased severity of anxiety symptoms initially (Gollan et al., 2012; Montgomery, Sheehan,
Meoni, Haudiquet, & Hackett, 2002). Thus, the field is in search of alternative anxiolytic
pharmaceuticals. Oxytocin administration is one promising option.
Oxytocin is endogenously released in response to stressful stimuli and reduces activity in
the amygdala and HPA axis, thus serving as a natural anxiolytic (Sobota, Mihara, Forrest,
Featherstone, & Siegel, 2015; Viero et al., 2010). Preclinical studies have produced promising
findings that suggest oxytocin administration may provide anxiety relief (see Meyer-Lindenberg,
Domes, Kirsch, & Heinrichs, 2011). For example, mice administered oxytocin over a 5 day
period displayed significant decreases in blood pressure and cortisol levels (Petersson, Alster,
Lundeberg, & Uvnäs-Moberg, 1996). Subchronic oxytocin administration in mice has also
shown to reduce anxiety-related behaviors (using open field, four-plate, and elevated plus maze
tasks) and reduce amygdala activity (using EEG recordings) (Mantella, Vollmer, Li, & Amico,
2003; Neumann & Landgraf, 2012; Ring et al., 2006; Sobota et al., 2015). Anxiogenic stimuli
have shown to stimulate CNS and peripheral oxytocin systems, leading some researchers to
suggest endogenous oxytocin may serve as a natural anxiolytic and that an imbalance in the
oxytocin system may play a role in the etiology of anxiety disorders (Engelmann, Landgraf, &
Wotjak, 2004; Neumann & Slattery, 2016). Although clinical trials administering oxytocin have
shown promise, such as a reduction in HPA axis activity, lower cortisol, lowered ACTH, and
reduced amygdala activity (Dodhia et al., 2014; Parker, Buckmaster, Schatzberg, & Lyons, 2005;
Windle, Shanks, Lightman, & Ingram, 1997) many questions, mostly surrounding the
mechanism of action and required dosing parameters, need to be addressed before this treatment
becomes mainstream (see Guastella & Hickie, 2016; Veening & Oliver, 2013).
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Addiction
The DSM 5 (2013) explains addiction, or substance abuse disorder specifically, as a
dysfunctional habit that causes affliction or distress as indicated by maladaptive social skills,
impaired restraint, tolerance and withdrawal symptoms from substance. NIDA (2015) reports
that addiction costs over $700 billion dollars annually due to lost work productivity, health care,
and crime associated with addiction. The anterior cingulate, orbital cortex, and temporal lobe
(includes amygdala) has been shown through functional imaging studies to be interactive during
drug craving (Everitt & Robbins, 2005). Everitt and Robbins (2005) suggest that drug seeking
may be influenced by mechanisms in the medial PFC, amygdala, and the hippocampus through
the connections to the nucleus accumbens.
The mesolimbic dopaminergic pathway has long been identified as playing a key role in
addiction-related behaviors (Koob & Le Moal, 1997; Volkow, Fowler, Wang, & Swanson,
2004). While different drugs of abuse affect different parts of the brain, the common trait is
increased dopamine release in limbic brain regions. The NAc is responsible for the primary
reinforcing effects of drugs, while the amygdala and hippocampus facilitate conditioned learning
(Feltenstein & See, 2008; Salgado & Kaplitt, 2015). Animal studies have shown an attenuation
of cocaine and heroin self-administration after lesions of the VTA or NAc (Roberts & Koob,
1982; Hubner & Koob, 1990). Furthermore, dopamine antagonist or synthesis inhibition also
decreased self-administration (Ikemoto, Yang, & Tan, 2015; Feltenstein & See, 2008). Animal
studies will self-administrate opioids into the VTA and NAc reliably but not consistently in other
brain regions. Rat and monkey studies have demonstrated that self-administration of
amphetamines is consistent in the orbitofrontal cortex (Phillips, Mora, & Rolls, 1981), the
amygdala and nucleus accumbens (Chevrette, Stellar, Hesse, & Markou, 2002).
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Oxytocin has recently been identified as a potential modulator implicated in the biology
of drug addiction (Buisman-Pijlman, Sumracki, Gordon, Hull, Carter, & Tops, 2014; Leong,
Zhou, Ghee, See, & Reichel, 2016; Kovács, Sarnyai, & Szabó, 1998; Sarnyai & Kovács, 2014).
Many animal studies have found that oxytocin administration can specifically reduce behavioral
responses to psychostimulants (for review see Carson, Guastella, Taylor, & McGregor, 2013).
Despite widespread abuse and detrimental health effects of psychostimulants (such as cocaine
and amphetamines) in our culture, no effective pharmacological treatments are currently
available (Kaye, Darke, Duflou, & McKetin, 2008; Lee & Rawson, 2008; Rose & Grant, 2008),
which emphasizes the excitement surrounding these preclinical studies of oxytocin and
addiction. Oxytocin impaired methamphetamine-induced conditioned place preference and
stress-induced reinstatement (Qi et al., 2009), and oxytocin has been shown to decrease lever
pressing in both methamphetamine and cocaine self-administration studies as well as reduce drug
seeking after extinction (Leong et al., 2016; Cox, Young, See, & Reichel, 2013; Zhou et al.,
2014). Locomotor hyperactivity and constant sniffing behavior observed following cocaine
administration were both attenuated by injections of oxytocin (Leong et al., 2016; Sarnyai and
Kovacs, 1994). Given this support for the use of oxytocin to combat the effects of drugs of
abuse, many clinical trials have begun testing this, and although most results are pending, some
have already shown promise (see Lee & Weerts, 2016).

Current Study
The proposed study aims to determine the effects of systemic oxytocin administration on
mesolimbic dopamine transmission in brain areas associated with anxiety (amygdala) and
addiction (NAc). In vivo fixed potential amperometry with carbon fiber recording electrodes
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will be used to measure real-time stimulation-evoked dopamine release in anesthetized mice in
response to subchronic and acute oxytocin administration. With the mice anesthetized and their
dopamine systems not being naturally activated, we will mimic environmentally activated
patterns via electrical stimulation (Lester et al., 2010). Given that both the amygdala and NAc
receive dopaminergic input from cell bodies in the VTA, the VTA will be our electrical
stimulation site. Anxiolytic drugs have shown to reduce dopamine release in the amygdala (Coco
et al., 1992), and oxytocin has shown to attenuate anxiety-related behaviors (Ring et al., 2006;
Sobota et al., 2015). Thus, we expect that systemic oxytocin administration will reduce VTA
stimulation-evoked dopamine release in the amygdala. As mentioned above, oxytocin is also
being evaluated as a potential treatment for drug addiction, and our recordings in the NAc will
shed light on potential mechanisms for this therapeutic use. In order to determine the effect of
oxytocin treatment on psychostimulant addiction, some mice will receive a drug challenge of
nomifensine, which is a dopamine reuptake blocker with a similar neuropharmacological
mechanism as cocaine. Our hypothesis is that oxytocin pretreatment will attenuate the
psychostimulant-induced increase in NAc dopamine release. To our knowledge, no studies have
measured in vivo real-time dopamine release following oxytocin administration; therefore, the
results of the present study will be extremely interesting and beneficial to basic scientists aiming
to understand neurochemical interactions but also to clinicians interested in using oxytocin as a
treatment option.

Methods
All procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Memphis and were also aligned with those outlined in The Public
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Health Service Policy on Humane Care and Use of Laboratory Animals (National Institutes of
Health 2012) and the Guidelines for the Care and Use of Mammals in Neuroscience and
Behavioral Research (National Research Council 2003).

Subjects
Fifty-two male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA), between
3-5 months, were housed 3-5 per cage. Cages were kept in a temperature (21± 1° C) controlled
room with a 12 h light/ 12h dark cycle. Food and water will be available ad libitum.

Apparatus and Materials
Stimulation-evoked dopamine release was measured using in vivo fixed potential
amperometry with carbon fiber microelectrodes. Amperometry is an electrochemical technique
in which a constant potential is delivered to an electrode. We chose 0.8V since our molecule of
interest, dopamine, oxidizes at 0.6V. Thus, the recorded current was a representation of the
amount of extracellular dopamine efflux following electrical stimulation (Carter & Shieh, 2015).
Pharmacological studies using the same electrical stimulation sites have confirmed these
recorded current changes to be dopamine based (Lee et al., 2006; Mittleman, Goldowitz, Heck,
& Blaha, 2008). Fixed potential amperometry is an established technique for real-time (10K
samples/sec) recording of stimulation-evoked dopamine release in cortical and subcortical brain
regions (Forster & Blaha, 2003; Lester et al., 2010).
Our lab consists of 3 functional amperometry stations, each equipped with a stereotaxic
frame and electrode carriers (David Kopf Instruments, CA, USA), a programmable stimulator
(Iso-Flex/Master 8, AMPI, Israel), and an electrometer (e-corder 401 and Picostat, Edaq Inc.,
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CO, USA) connected to a computer. Each amperometry station was surrounded by a faraday
cage to block interfering electrical noise. Approval was given by the Environmental Health and
Safety department at the University of Memphis for the standard operating procedures
concerning urethane (U2500 Sigma-Aldrich), oxytocin (03251 Sigma-Aldrich), nomifensine
(N1530 Sigma-Aldrich), and dopamine (H8502 Sigma-Aldrich).

Procedure
The subchronic oxytocin pretreatment regimen of this proposed study was the same as
that used by previous behavioral studies showing that oxytocin is capable of improving social
interactions, reducing anxiety-related behaviors, and reducing amygdala EEG activity in
adolescent and adult mice (Sobota et al., 2015; Teng et al., 2016). The pretreatment consisted of
each mouse receiving 4 i.p. injections of either saline (vehicle) or oxytocin (1.0 mg/kg) across 8
days with a minimum of 48 hours between each injection. The injection was given at the same
time on sequential weekdays. Forty-eight hours after the last injection, dopamine release was
measured using fixed potential amperometry.
The amperometry procedure began with each mouse being anesthetized by urethane (1.5
g/kg, i.p.). The mouse was evaluated 10 minutes after injection by three different reflex checks
(eye-blink, mild tail and foot-pinch) to ensure induction of anesthesia. If necessary, a
supplemental dose of urethane (0.5 g/kg, i.p.) was given to mouse. All records of anesthetized
animals were kept in a designated lab notebook. The mouse was then placed in a stereotaxic
frame with a mouse head-holder adapter for electrode placement. Body temperature was kept at
37 ± 0.5 °C as well as monitored and maintained throughout procedure with a temperatureregulated heating pad (TC-1000; CWE, NY).
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A longitudinal incision was made to expose the surface of the skull. Three trephine holes
(~ 1-1.5 mm o.d.) were drilled through the skull. A stimulating electrode (SNE-100; Rhodes
Medical Co., CA, USA) was inserted into the VTA (coordinates in mm from bregma: AP + 3.3,
ML + 0.3, and DV – 4.0 from dura). A stainless-steel auxiliary and Ag/AgCl reference electrode
combination was positioned in contact with contralateral cortical tissue approximately 2.0 mm
posterior to bregma. A carbon fiber recording electrode was either implanted in the left amygdala
or nucleus accumbens (amygdala coordinates in mm from bregma: AP +1.0, ML +2.5, and DV 5.0 from dura; nucleus accumbens coordinates in mm from bregma: AP +1.5, ML +1.0, and DV
-4.0 from dura; Paxinos & Franklin, 2001).
A series of cathodal monophasic current pulses (20 pulses at 50 Hz applied every 30 secs
over a 1 hr recording period) were delivered to the stimulating electrode. Following a 10-min
baseline recording of stimulation-evoked dopamine release, mice received an i.p. injection of
either saline (0.9%), oxytocin (1.0 mg/kg), or the selective dopamine transporter (DAT) inhibitor
nomifensine (10 mg/kg). See Table 1 for a list of experimental groups. Recordings proceeded for
1 hour following the drug challenge. At the end of each experiment, a direct anodic current
(100µAmps for 10 sec) was applied to the stimulating electrode to mark electrode placement.
Mice were then euthanized (intracardial urethane 0.345g/ml). The brain was removed and
prepared in 30%/10% sucrose/formalin plus 0.1% potassium ferricyanide for cryostat sectioning.
Electrode placement was confirmed with a light microscope and recorded on coronal diagrams
(Paxinos & Franklin, 2001). The mean change in dopamine oxidation current (nAmp),
corresponding to stimulation-evoked dopamine efflux, was converted to a mean dopamine
concentration (µM) by post-experiment in vitro calibration of the carbon fiber electrode in
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solutions of dopamine (0.5-2.0 µM) using a flow injection system (Michael and Wightman,
1999).
Data analysis
In order to quantify the recorded dopamine efflux, data points occurring at 0.25 sec preand 10 sec post-stimulation were extracted at 5 min intervals. From baseline recordings we
compared the effects of the subchronic pretreatment (oxytocin or saline) on dopamine release
(the magnitude of the response peak) and dopamine half-life (i.e. the time for 50% decrease from
the maximum evoked increase to the prestimulus baseline level). Independent samples t-tests
were used to determine differences between pretreatment groups in baseline dopamine release
and half-life. In order to determine the effect of the i.p. drug challenge (oxytocin, nomifensine,
or saline) during amperometric recordings, changes in stimulation-evoked dopamine release and
half-life were converted to mean percent change with respect to baseline (Lester, Miller, Pate, &
Blaha, 2008). A repeated measures ANOVA was used to determine the effect of pretreatment on
percent change in dopamine release and half-life over time following the drug challenge. When
appropriate a one way ANOVA with Tukey’s HSD posthoc tests was used to determine group
differences at certain time points. All statistical analyses were conducted using IBM SPSS
Statistics 23 (IBM Corp).

Results
Histology
The tips of the stimulating electrodes were positioned within the anatomical boundaries
of the VTA. The placements of the electrochemical recording electrode surfaces were confined
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to the core of the basolateral amygdala (BLA) or NAc. Figure 1A-C is a depiction of the
placement ranges and coordinates from bregma (Paxinos & Franklin, 2001).

Dopamine efflux in the amygdala
Stimulation-evoked dopamine efflux in the amygdala was compared between the two
pretreatment groups, subchronic oxytocin (n = 14) or saline (n = 12) (Fig 2A). Two specific
components of these responses were quantified: dopamine release (the magnitude of the response
peak) and dopamine half-life (the time dopamine remained in the synapse). Dopamine release in
the amygdala did not differ between oxytocin and saline pretreated mice; t (24) = 0.092, p = .927
(Fig 2B). Likewise, there was no significant difference in dopamine half-life between the
pretreatment groups; t (24) = 1.162, p = .257 (Fig 2C).

Dopamine efflux in the amygdala following oxytocin administration
During amperometric recordings in the amygdala, a subset of mice received an i.p. drug
challenge of either oxytocin (1 mg/kg; n = 4 from each pretreatment group) or saline (n = 4 from
each pretreatment group). Percent change in dopamine release and dopamine half-life were
analyzed at 20, 40, and 60 min post drug challenge (oxytocin or saline). A two-way repeated
measures ANOVA revealed a nearly significant pretreatment x drug challenge interaction on
percent change in dopamine release over time [F(3, 36) = 2.85, p = .051, np2 = 0.19], indicating
the effect of the oxytocin injection on dopamine release differed based on whether the animal
had been pretreated with oxytocin or saline. Further investigations using one-way ANOVAs
revealed that at 20 min post oxytocin/saline injection, no alterations in dopamine release were
observed in either pretreatment group [F (3,12) = 0.68, p = .579]. However, at 40 and 60 min
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post oxytocin/saline differences in dopamine release were observed between pretreatment groups
[40 min: F (3,12) = 6.08, p = .009, np2 = 0.60; 60 min: F (3,12) = 9.06, p = .002, np2 = 0.69].
Specifically, oxytocin administration decreased dopamine release at these time points in oxytocin
pretreated mice relative to saline pretreated mice (sal-oxy vs. oxy-oxy: p = .017 and .008 at 40
and 60 min) (Fig 3A). Regarding the effect of the oxytocin drug challenge on dopamine halflife, a two-way repeated measures ANOVA revealed no interaction between pretreatment and
drug challenge on percent change in dopamine half-life over time [F(3, 36) = 1.68, p = .188] (Fig
3B).

Dopamine efflux in the amygdala following nomifensine administration
During amperometric recordings in the amygdala, a subset of mice received an i.p. drug
challenge of the dopamine reuptake blocker nomifensine (10 mg/kg, n = 4-5 per pretreatment
group). Percent change in stimulation-evoked dopamine release and half-life following
nomifensine were compared with mice that received an i.p. saline injection (n = 4 from each
pretreatment group) 20, 40, and 60 min post injection. A two-way repeated measures ANOVA
revealed no interaction between pretreatment and nomifensine drug challenge on percent change
in dopamine release over time [F(3, 39) = 0.72, p = .55] (Fig 3C). Similarly, regarding the effect
of the nomifensine drug challenge on dopamine half-life, a two-way repeated measures ANOVA
revealed no interaction between pretreatment and drug challenge on percent change in dopamine
half-life over time [F(3, 39) = 0.50, p = .69]. However, there was a significant main effect of
drug challenge on percent change in dopamine half-life over time [F(3,39) = 10.11, p < .001, np2
= 0.438]. Specifically, relative to saline injections, nomifensine significantly increased the
dopamine half-life at the 20 and 40 min time points in saline pretreated mice (sal-sal vs. sal-
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nomi: p = .017 at 20 min; sal-sal vs. sal-nomi: p = .029 at 40 min). Interestingly though, in
oxytocin pretreated mice, nomifensine did not significantly alter dopamine half-life at these time
points (oxy-sal vs. oxy-nomi: p = .213 at 20 min; oxy-sal vs. oxy-nomi: p = .130 at 40 min) (Fig
3D).

Dopamine efflux in the NAc
Stimulation-evoked dopamine efflux in the NAc was compared between the two
pretreatment groups, subchronic oxytocin (n = 15) or saline (n = 12) (Fig 4A). Oxytocin
pretreated mice had a significantly lower baseline dopamine release compared to the saline
pretreated mice; t (25) = 2.80, p = 0.01 (Fig 4B). The half-lives of baseline dopamine responses
did not differ between the mice pretreated with oxytocin and saline; t (25) = 1.17, p = 0.25 (Fig
4C).

Dopamine efflux in the NAc following oxytocin administration
During amperometric recordings in the NAc, a subset of mice received an i.p. drug
challenge of either oxytocin (1 mg/kg; n = 4-5 per pretreatment group) or saline (n = 4-5 per
pretreatment group). Percent change in dopamine release and dopamine half-life were analyzed
at 20, 40, and 60 min post drug challenge (oxytocin or saline). A two-way repeated measures
ANOVA revealed no interaction between pretreatment and oxytocin drug challenge on percent
change in NAc dopamine release over time [F(3, 42) = 0.55, p = .649] and no main effect of
oxytocin drug challenge over time on dopamine release [F(3, 42) = 0.34, p = .799] (Fig 5A).
Likewise, no interaction was observed between pretreatment and oxytocin drug challenge on
percent change in dopamine half-life over time [F(3, 42) = 1.41, p = .254] with no main effect of
oxytocin drug challenge over time on dopamine half-life [F(3, 42) = 0.24, p = .867] (Fig 5B).
15

These results indicate that the oxytocin drug challenge during amperometric recordings did not
alter NAc dopamine release or half-life in either pretreatment group (oxytocin or saline).

Dopamine efflux in the NAc following nomifensine administration
During amperometric recordings in the NAc, a subset of mice received an i.p. drug
challenge of the dopamine reuptake blocker nomifensine (10 mg/kg, n = 4-5 per pretreatment
group). Percent change in stimulation-evoked dopamine release and half-life following
nomifensine were compared with mice that received an i.p. saline injection (n = 4-5 per
pretreatment group) 20, 40, and 60 min post injection. A two-way repeated measures ANOVA
revealed no interaction between pretreatment and nomifensine drug challenge on percent change
in dopamine release over time [F(3, 42) = 0.96, p = .420] (Fig 5C), indicating nomifensine had a
similar effect on NAc dopamine release in both pretreatment groups (saline and oxytocin).
However, regarding the effect of the nomifensine drug challenge on dopamine half-life in the
NAc, a two-way repeated measures ANOVA revealed a trending interaction of pretreatment x
drug challenge on percent change in dopamine half-life over time [F(3, 42) = 2.48, p = .074, np2
= 0.15], indicating the effect of nomifensine on dopamine half-life differed based on whether the
animal had been pretreated with oxytocin or saline. One way ANOVAs showed significant
differences in percent change in dopamine half-life following the nomifensine/saline drug
challenge between pretreatment groups at all time points [20 min: F (3,14) = 15.86, p < .001, np2
= 0.77; 40 min: F (3,14) = 16.83, p < .001, np2 = 0.78; 60 min: F (3,14) = 11.80, p < .001, np2 =
0.72]. Post hoc analyses revealed that nomifensine significantly increased dopamine half-life at
all time points in both pretreatment groups (p < 0.05), but nomifensine administration increased
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dopamine half-life to a lesser extent in oxytocin pretreated mice compared to saline pretreated
mice at 20 min (sal-nomi vs. oxy-nomi: p = 0.04) (Fig 5D).

Discussion
Studies at both the preclinical and clinical level have demonstrated that oxytocin may
play a role in multiple behavioral disorders including anxiety (see Meyer-Lindenberg et al.,
2011) and addiction (see Kovács et al., 1998). Dopamine has also been associated with anxiety
(see Zarrindast & Khakpai, 2015) and addiction (see Volkow et al., 2004); however, the impact
of oxytocin administration on dopamine transmission is not clear. The current study investigated
the effects of subchronic oxytocin administration on the release of mesolimbic dopamine in the
amygdala and NAc. Subchronic pretreatment dosages were chosen based on previous behavioral
studies (Sobota et al., 2015; Teng et al., 2016) and consisted of 4 i.p. injections of oxytocin (1
mg/kg) or saline, with each injection scheduled 48 hours apart. Dopamine release was quantified
using in vivo fixed potential amperometry 48 hours after the final pretreatment injection.
Baseline levels of stimulation-evoked dopamine release were established and followed by an i.p.
drug challenge of acute oxytocin (1 mg/kg), the dopamine reuptake blocker nomifensine (10
mg/kg), or saline (vehicle control).
To our knowledge, the present study is the first to show that systemic oxytocin
administration can lower baseline dopamine release. Oxytocin, a nonapeptide characterized by a
six amino acid ring structure with a three amino acid tail, should be too large to cross the blood
brain barrier (Ermisch, Rühle, Landgraf, & Hess, 1985; Meisenberg & Simmons, 1983).
However, our results indicate that peripheral administration of oxytocin has the ability to
influence neurotransmission. Several studies have shown elevated oxytocin levels in in cerebral
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spinal fluid following peripheral administration (Dal Monte, Noble, Turchi, Cummins, &
Averbeck, 2014; Freeman et al., 2016; Lee et al., 2018). Neumann et al. (2013) used
microdialysis to specifically confirm increased concentrations of oxytocin in the hippocampus,
amygdala, and plasma of rats and mice following both intranasal and intraperitoneal routes.
Some have suggested peripheral administration of oxytocin stimulates release of endogenous
central oxytocin via activation of hypothalamic nuclei (Carson, Cornish, Guastella, Taylor, &
McGregor, 2010; Maejima et al., 2015). However, recently Lee et al. (2018) utilized a sensitive
and specific quantitative mass spectrometry assay, capable of distinguishing endogenous and
administered oxytocin, to confirm oxytocin crossed the blood brain barrier in rhesus macaques
following both intranasal and intravenous administration. Although our experimental protocol
does not allow conclusions to be drawn regarding the routes of transport and pharmacodynamics
of administered oxytocin, our data supports the growing literature showing peripherally
administered oxytocin has CNS impact. Our data supplements the field by revealing an
influential role of oxytocin on functional mesolimbic dopamine transmission.

Subchronic oxytocin administration altered dopamine transmission in the amygdala
Typical anxiolytic drugs, which generally directly agonize GABA, have been shown to
indirectly reduce mesolimbic dopamine activity evoked by both electrical stimulation (Gomez-A
et al., 2017) and stressful stimuli (Coco et al., 1992). Therefore, we expected oxytocin
administration, which has shown to have anxiolytic effects behaviorally (Kim et al., 2011;
Sobota et al., 2015), would reduce dopamine release in the amygdala. Amperometric recordings
took place 48 hours following the last pretreatment injection. In the amygdala, no differences in
baseline dopamine release or half-life were observed between pretreatment groups. Thus,
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subchronic oxytocin administration did not have a lasting effect (at least not spanning 48 hours)
on stimulation-evoked dopamine release or reuptake kinetics. However, subchronic oxytocin
administration did alter the functioning of this brain region, priming it to respond differently to
future oxytocin administrations. Oxytocin administered during dopamine recordings resulted in
attenuated dopamine release but only in the oxytocin pretreated group (meaning this was the 5th
oxytocin injection for this group of mice). Likewise, using the same subchronic oxytocin
administration and EEG recordings in the same mouse strain, Sobota et al. (2015) observed a
reduction in amygdala activity following oxytocin administration. Given that dopamine
transmission in the saline pretreated mice was not affected in the current study, an acute injection
of oxytocin (first exposure) at this dose was not sufficient to decrease amygdalar dopamine
release.
The response to the dopamine reuptake blocker nomifensine was also influenced by
subchronic oxytocin pretreatment. Saline pretreated mice showed an increase in dopamine halflife following nomifensine administration compared to saline administration, as expected;
however, nomifensine did not have the same impact in oxytocin pretreated mice. Dopamine
reuptake blockers, similar to nomifensine used in the present study, are regularly prescribed,
such as Ritalin and Adderall for ADHD, and abused, such as cocaine and amphetamines.
Anxiety is a common side effect of such drugs (Coughlin, Cohen, Mulqueen, Ferracioli-Oda,
Stuckelman, & Bloch, 2015; Koob, 2009). The present results suggest repeated oxytocin
treatment may lessen the amygdalar effect of these dopaminergic drugs to some degree.
Correspondingly, Morales-Rivera et al. (2014) showed that oxytocin treatment mediated anxiety
behavioral responses triggered by cues previously paired with cocaine intake. The present
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findings can help provide a neurochemical mechanism to studies relating oxytocin with
amygdala-associated behavioral functions.
We examined the influence of oxytocin administration on dopamine in the amygdala due
to the well-known role of this brain region in anxiety and input from midbrain dopamine neurons
(de la Mora, 2010). In the amygdala, increased dopamine concentrations have been observed
following stressful conditions such as handling, being restrained, or conditioned fear paradigms
(Diaz et al., 2011; Forster et al., 2012; Torres, Gamaro, Vasconcellos, Silveira, & Dalmaz, 2002),
and dopamine antagonists elicited anxiolytic affects when microinjected into the basolateral
amygdala (Linsambarth, Moraga-Amaro, Quintana-Donoso, Rojas, & Stehberg, 2017).
Oxytocin seems to play a role in the excitability of the amygdala as well. In elevated plus maze
tests, oxytocin deficient mice displayed anxious behaviors (less time spent in open arms and less
rearing), which were mitigated by oxytocin administration (Mantella et al., 2003; Neumann &
Landgraf, 2012; Ring et al., 2006). These studies, combined with previously mentioned studies
showing endogenous oxytocin levels rise in stressful conditions, suggest oxytocin plays a natural
role in relieving anxiety (see Engelmann, Landgraf, & Wotjak, 2004; Neumann & Slattery,
2016). Clinical studies support this notion in that patients with social anxiety present increased
amygdala activation (Ziegler, Dannlowski, Brauer, Stevens, Laeger, & Wittman, 2015) and
oxytocin administration decreases amygdala activity associated with generalized social anxiety
disorder (Dodhia et al., 2014). Given that dopamine is excitatory in the amygdala (Diaz et al.,
2011; Rosenkranz & Grace, 1999), the present results indicate oxytocin administration may have
anxiolytic properties due to its regulatory role over dopamine transmission in the amygdala, at
least in part. Thus, an interesting follow-up to the present study would be to repeat these
procedures in mice having been exposed to a stress-inducing paradigm.
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Subchronic oxytocin administration altered dopamine transmission in the nucleus
accumbens
At the time of amperometric recordings, 48 hours after the last subchronic oxytocin
pretreatment, oxytocin pretreated mice displayed reduced accumbal dopamine release compared
to saline pretreated mice. Interestingly, however, oxytocin administered during amperometric
recordings did not alter dopamine release or half-life, indicating no acute/immediate effect of
oxytocin in dopamine neurotransmission in this brain region. These findings suggest oxytocin
lacks reinforcing properties, which mirrors behavioral findings in which oxytocin did not
produce conditioned place preference in mice when administered via intracutaneous,
intraperitoneal (Baracz et al., 2012) or intranasal routes (Kosaki & Watanabe, 2016). These
findings may be sex and dose-dependent given female rodents have been shown to selfadminister oxytocin and develop conditioned place preference for oxytocin delivered at higher
doses through intracerebroventricular cannula (Donhoffner, Goings, Atabaki, & Wood, 2016;
Kent et al., 2016) or intraperitoneal injection 8 mg/kg (Liberzon, Trujillo, Akil, & Young, 1997).
Oxytocin has been shown to attenuate self-administration, conditioned place preference,
and locomotor hyperactivity related to use psychostimulant and other dopamine agonists in
animal models (Leong et al., 2016; Carson et al., 2010; Qi et al., 2009; Zhou et al., 2014), and as
expected, in the present study, mice pretreated with subchronic oxytocin had a reduced
dopaminergic response to the drug challenge of nomifensine, a dopamine reuptake blocker with a
similar neuromechanism as cocaine. Specifically, 20 min post nomifensine injection, dopamine
half-life in the NAc of oxytocin pretreated mice was increased relative to baseline (prenomifensine levels), but to a significantly reduced extent (nearly half as much) as saline
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pretreated mice. Dopamine half-life is commonly used as an indication of the influence of a
DAT inhibitor (Mittleman et al., 2008; Siciliano, Calipari, Ferris, and Jones 2014). Attenuated
drug-induced increases in dopamine half-life (a measure of time in the synapse) may result in a
diminished salience for the psychostimulant. At 40 and 60 min post injection, the nomifensineinduced increases in dopamine half-life were the same in both pretreatment groups, but the
observed reduced dopaminergic response at the 20 min mark may have implications for the
rewarding effects of dopamine agonists. The sooner an increase in dopamine efflux occurs
following a drug administration, the more reinforcing ability that drug has (Volkow and Morales,
2015); thus, our data indicates nomifensine may be less rewarding following subchronic
administration of oxytocin. These findings can help provide a neurochemical mechanism for
studies relating oxytocin with NAc-associated behavioral functions.
Clinical studies have begun trying to determine how these effects can be put to use in the
human population to combat maladaptive drug use. Recent clinical studies have shown that
oxytocin reduces the withdrawal symptoms of alcohol (Pedersen et al., 2013), attenuated cocaine
craving in cocaine-dependent users receiving methadone (Stauffer et al., 2016), and decreased
the amount of cannabis consumed daily by habitual cannabis smokers (Sherman, Baker, &
McRae-Clark, 2017; McRae-Clark, Baker, Moran-Santa Maria, & Brady, 2013). Given these
clinical findings, an interesting follow-up to the present study would be to repeat these
procedures in mice previously exposed to and dependent on a psychostimulant.

Conclusion
The present study is the first to our knowledge to show that systemic oxytocin
administration can alter dopamine release in limbic structures. The effect of systemic oxytocin,
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as least at the present dose in this mouse strain, seems to be cumulative given that acute
injections in oxytocin-naïve mice had no dopaminergic effect in either limbic brain region. In
the amygdala, mice pretreated with subchronic oxytocin displayed decreased dopamine release
following oxytocin administration relative to saline pretreated mice. In the NAc, mice pretreated
with subchronic oxytocin displayed decreased baseline dopamine release and a reduced
dopaminergic response to a dopamine agonist. Together these results provide neurochemical
support for preclinical and clinical studies suggesting oxytocin may be useful in treating aspects
of anxiety and drug addiction. The prospect of an anxiolytic without abuse liability is
particularly attractive given the current issues surrounding benzodiazepines. Reciprocally, a
potential pharmaceutical that decreases the rewarding effects of psychostimulants while also
reducing anxiety, a common withdrawal symptom, is enticing and warrants further study. The
present study provides a starting point for deciphering the relationship between systemic
oxytocin administration and dopamine transmission. More studies are necessary to determine
the relative effects of oxytocin administration in both sexes, as oxytocin expression levels (de
Vries, 2008) and oxytocin-mediated behaviors (see Dumais & Veenema, 2016) are known to
differ between sexes. Overall, the present study adds to our understanding of the neural effects
of oxytocin, which is critical given the potential of therapeutic uses for this drug.
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Appendix
Table 1
Experimental groups
Pre-treatment

Recording Site

Systemic drug during recording

N

Subchronic Oxytocin

Amygdala

Oxytocin

4

Nomifensine

5

Saline

4

Oxytocin

5

Nomifensine

5

Saline

5

Oxytocin

4

Nomifensine

4

Saline

4

Oxytocin

4

Nomifensine

4

Saline

4

--

52

Nucleus accumbens

Subchronic Saline

Amygdala

Nucleus Accumbens

--

--
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Figure 1. Representative coronal sections of the mouse brain (adapted from the atlas of Paxinos
and Franklin, 2001), with grey shaded areas indicating the placements of (A) stimulating
electrodes in the ventral tegmental area (VTA) and amperometric recording electrodes in the (B)
nucleus accumbens (NAc) or (C) basolateral amygdala (BLA). Numbers correspond to mm from
bregma.
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Figure 2. Amperometric recordings of stimulation-evoked dopamine release in the amygdala.
(A) Profiles illustrate example responses from each pretreatment group. Time zero indicates the
start of the stimulation train of 20 pulses at 50 Hz. Neither means (± SEM) in (B) dopamine
release or (C) dopamine half-life, i.e. the time required for 50% decrease from the maximum
evoked release to the prestimulus baseline level, were different between pretreatment groups.
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Figure 3. Amperometric recordings of stimulation-evoked dopamine release in the amygdala
following an intraperitoneal drug challenge of either saline (control), oxytocin, or nomifensine
(dopamine reuptake blocker). (A) Oxytocin administration significantly decreased dopamine
release at 40 and 60 min post injection but only in the mice subchronically pretreated with
oxytocin. * indicates significant difference between pretreatment groups. (B) Oxytocin
administration did not alter dopamine half-life in any pretreatment group. (C) Nomifensine did
not alter dopamine release in any pretreatment group. (D) Nomifensine significantly increased
the dopamine half-life of mice pretreated with saline but not oxytocin. + indicates significant
difference between drug challenges (nomifensine and saline). Legend signifies “pretreatment drug challenge”; for example, “oxy-nomi” denotes the group of mice pretreated with subchronic
oxytocin and administered nomifensine as the drug challenge during amperometric recordings.
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Figure 4. Amperometric recordings of stimulation-evoked dopamine release in the nucleus
accumbens (NAc). (A) Profiles illustrate example responses from each pretreatment group.
Time zero indicates the start of the stimulation train of 20 pulses at 50 Hz. (B) Mean (± SEM)
differences in dopamine release were observed between treatment groups. * indicates p < 0.05.
(C) No differences in mean (± SEM) dopamine half-life, i.e. the time required for 50% decrease
from the maximum evoked release to the prestimulus baseline level, were observed between
pretreatment groups.
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Figure 5. Amperometric recordings of stimulation-evoked dopamine release in the nucleus
accumbens (NAc) following an intraperitoneal drug challenge of either saline (control),
oxytocin, or nomifensine (dopamine reuptake blocker). Oxytocin administration did not alter
(A) dopamine release or (B) dopamine half-life in any pretreatment group relative to saline. (C)
Nomifensine acted similarly, increasing NAc dopamine release, in both pretreatment groups.
(D) Nomifensine also significantly increased the dopamine half-life of mice in both pretreatment
groups, but to a greater degree at 20 min in the mice pretreated with saline. * indicates
significant difference between pretreatment groups. Legend signifies “pretreatment - drug
challenge”; for example, “oxy-nomi” denotes the group of mice pretreated with subchronic
oxytocin and administered nomifensine as the drug challenge during amperometric recordings.
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